495 results about "Extracellular vesicle" patented technology

Disclosed are methods, compositions, devices, and kits for the isolation of brain-specific exosomes. Specifically, methods, compositions, devices, and Unbound kits comprising an isolated brain-specific extracellular vesicle or exosome joined to a first binding agent that is specific for tau, β-amyloid, SlOO β, neuron-specific enolase, glycoprotein A2B5, CD133, NQ01, synaptophysin, neuronal nuclei, MAB 1569, polysialic acid-neural cell adhesion molecule (PSA-NCAM), or neurogenic differentiation 1 (NeuroD or Beta2), or glycosylated or phosphorylated forms of these molecules, are provided.

The present invention provides compositions of yeast extracellular vesicles comprising biologically active molecules, methods for making the same, and methods for the use of the yeast extracellular vesicles to deliver biologically active molecules to target cells. In addition, the invention provides cells and compositions comprising the biologically active molecules and vesicles, which can be used as transfection reagents. The invention further provides methods for producing said compositions of biologically active molecules with vesicles as well as the cells that produce those compositions. Compositions and methods for delivering biologically active molecules, such as a small molecule, a DNA expression plasmid, an RNA molecule, a peptide, or a protein, to cells and/or tissues are provided. The compositions and cells are useful, for example, in delivering biologically active RNA molecules to cells to modulate target gene expression in the diagnosis, prevention, amelioration, and/or treatment of diseases, disorders, or conditions in a subject or organism.

The present invention relates to extracellular vesicles (EVs) derived from gram-positive bacteria. In detail, the present invention provides animal models of disease using extracellular vesicles derived from gram-positive bacteria, provides a method for screening an active candidate substance which is capable of preventing or treating diseases through the animal models of disease, provides vaccines for preventing or treating diseases caused by extracellular vesicles derived from gram-positive bacteria, and provides a method for diagnosing the causative factors of diseases caused by gram-positive bacteria using extracellular vesicles.

The described invention provides compositions and methods for treating a susceptible subject at risk of pulmonary complications of an acute lung injury caused by a severe infection with a respiratory virus and for restoring lung function to donor lungs. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles (EVs) comprising one or more miRNAs and a pharmaceutically acceptable carrier. The population of EVs can be derived from a patient who has recovered from an infection with the respiratory virus or has been exposed to anti-viral antibodies through treatment, can be derived from MSCs of a normal healthy individual, can be modified by a viral vector, or can be synthetic.

The present invention disclosed a method of fabricating an antibody immunolipoplex nanoparticle (Ab-ILN) biochip and antibody tethered lipoplex nanoparticle (Ab-TLN) biochip. The aforementioned antibody-based lipoplex nanoparticle biochip or the related array contains molecular probes and is applied for detecting the presence of a disease or condition in a subject obtaining a body fluid sample by capturing and identifying both membrane protein and intra-vesicular DNA/RNA/proteins of extracellular vesicles (EVs).

The invention relates to the technical field of biological separation and extraction, in particular to an extracting method of extracellular vesicles. The method comprises the steps that a biologicalsample is provided; the biological sample is in contact with a capturing surface at least twice on the condition that impurities in the biological sample are partially or wholly reserved on the capturing surface, wherein the impurities are partial or whole other substances except the extracellular vesicles in the biological sample, and the capturing surface comprises an inner surface and/or outersurface of a spherical-particle porous material; when the impurities are partially or wholly reserved on the surface of a capture, breakthrough liquid is extracted liquid containing the extracellularvesicles; or the breakthrough liquid is further concentrated. By means of the method, the epicyte vesicles can be quickly separated and purified, the separation operation is simple, the single use cost is low, the separated sample in high in purity, the bioactivity of the sample is kept good, and the extracting method is applied to fundamental research in the aspects of biomarker discovery, biotherapy and the like and industrial production.

The invention discloses a preparation method of saliva extracellular vesicles and application of the saliva extracellular vesicles to molecular diagnosis.The preparation method includes the steps of removing high-abundance proteins from saliva samples, filtering out mucoproteins, separating and extracting the extracellular vesicles, characterizing the obtained extracellular vesicles, extracting extracellular vesicle proteins, identifying the extracellular vesicle proteins and applying the extracellular vesicle proteins to lung cancer biomarker discovery.Currently, a normalized saliva extracellular vesicle preparation technology is absent, and high-abundance protein interference and background impurity interference, existing in existing preparation technologies, result in shortcomings of low extracellular vesicle recovery rate, fewer identified proteins and the like, so that true extracellular vesicle proteomics information can be reflected difficultly.The preparation method of the saliva extracellular vesicles and application of the saliva extracellular vesicles to molecular diagnosis have the advantages that saliva of healthy adult volunteers and lung cancer patients is taken as the samples, and an affinity chromatography and membrane separation combined technology is adopted, so that after the high-abundance proteins and the mucoproteins of the saliva are removed, the extracellular vesicles in the saliva are extracted centrifugally, proteomes of the extracellular vesicles are analyzed and more extracellular vesicle proteins are identified.

The invention discloses a method for adsorbing and separating extracellular vesicles including exosomes secreted to a medium by cells based on an anion exchange resin, the extracellular vesicles including exosomes produced by the method, and application thereof. The method provided by the invention is simple and convenient to operate and only needs to use chromatographic tubes/columns and pipetteguns and other common laboratory consumables, does not require use of ultra centrifuges, saves cost and time; the obtained extracellular vesicles has high purity and large concentration, can be produced in a large scale, and is easy to be further applied clinically.

The present disclosure features compositions and methods related to the detection and molecular profiling of extracellular vesicles using fluorescent probes. These compositions and methods leverage the unique optoelectrical properties of quantum dots and fluorescently labeled nanoparticles, which allows reliable, real-time detection of extracellular vesicles and vesicle surface bound or lumenal molecules.

Disclosed in the specification is an anti-aging composition comprising, as an effective ingredient, extracellular vesicles that are complex physiologically active substances derived from lactic acid bacteria. The extracellular vesicles may be exosome-like vesicles with a diameter of 20 to 200 nm and the composition inhibits the expression of MMP-1 protein, thereby providing the effects of reducingskin wrinkles, improving skin elasticity, suppressing collagen reduction, and preventing ultraviolet light-induced skin damage.

The present invention relates to methods for loading extracellular vesicles (EVs) with a pharmacological agent. The invention discloses the use of cell-penetrating peptides as carriers into EVs, using either a non-covalent or covalent loading approach. Furthermore, the present invention pertains to medical uses and compositions comprising such pharmacological agent-loaded EVs.

The present invention pertains to an inventive release mechanism for extracellular vesicle (EV)-mediated intracellular and intramembrane delivery of therapeutic polypeptides. More specifically, the invention relates to EVs comprising polypeptide constructs which comprise a therapeutic polypeptide releasably attached to an exosomal polypeptide. Furthermore, the present invention pertains to manufacturing methods, pharmaceutical compositions, medical uses and applications, and various other embodiments related to the inventive EVs.

The present invention provides pharmaceutical compositions comprising a mesenchymal stromal cell (MSC) population, extracellular vesicles secreted from said MSC population, and a combination thereof, and methods of use thereof in treatment of a disease or disorder.

The invention provides an extracellular vesicle separation and enrichment method based on exclusion chromatography and an ultrafiltration technology. The extracellular vesicle separation and enrichment method comprises the following steps: mixing a fluorescent dye with a body fluid, adding a sample to an exclusion chromatographic column, collecting fractions according to fluorescence intensity, combining the fractions, sequentially treating the combined fractions with protease K and RNase A, and finally carrying out ultrafiltration concentration. The exclusion chromatography and the ultrafiltration method are combined to solve the problem of low product concentration of the exclusion chromatography, and the fluorescent dye is introduced as a tracing external reference, so that the fractionof EVs can be accurately positioned, and the EVs loss caused by damage of a filter membrane can be eliminated before entering the next operation. The invention also provides a kit capable of separating and enriching high-purity extracellular vesicles from body fluid. According to the method, the high-purity EVs can be separated from the body fluid without ultracentrifugation, and meanwhile, in cooperation with protease K and RNase A treatment, nucleic acid pollution from non-vesicle sources in the body fluid can be effectively eliminated, so that the nucleic acid purity of the extracellular vesicles is greatly improved.

The invention discloses biological ink for 3D (Three Dimensional) printing and a preparation method thereof. The biological ink for the 3D printing is prepared from the following raw materials in percentage by mass: 10 to 30 percent of an extracellular vesicle mixed suspension solution, 5 to 15 percent of a biological macromolecular material, 0.1 to 1 percent of dissolution promoter and the balance of water. The biological ink disclosed by the invention can be used for simulating extracellular matrix component, structure and biological activity characteristics better by utilizing advantages ofextracellular vesicles and characteristics of the biological macromolecular material and hydrogel.

The present invention provides a method of inducing activation of a non-potent or insufficiently potent cell to convert the cell into a tissue-effector cell, thereby producing an activation-induced tissue-effector cell suitable for use in cell therapy—e.g., an activated specialized tissue-effector cell (ASTEC) suitable for cell therapy for a particular tissue type. The present invention further provides activation-induced tissue-effector cells produced thereby, as well as extracellular vesicles, e.g., exosomes, derived therefrom (e.g., ASTEX). The present invention further provides a method of improving the efficacy of a cell therapy by converting non-potent or insufficiently potent cells into activation-induced tissue-effector cells having increased potency suitable for cell therapy. The present invention further provides a method for treating a disease or condition amenable to cell therapy in a subject in need thereof, the method comprising administering a therapeutically effective amount of activation-induced tissue-effector cells or extracellular vesicles derived therefrom.

The invention discloses 3D biology-printed hydrogel ink and a preparation method thereof. The 3D biology-printed hydrogel ink is prepared from the following components in percentage by weight: 1-10% of a solidifiable polymer, 1-10% of acellular matrix hydrogel, 1-10% of an extracellular vesicle suspension, 5-15% of a biomacromolecule material, 1-5% of a bioactive molecule, 0.1-0.5% of a solvent accelerating agent and the balance of water, and the total mass is 100%. According to the solidifiable polymer, water-soluble natural polysaccharide and natural high-polymer materials are adopted, and compatibility of the solidifiable polymer with cells is solved. In order to further improve the solidifiable polymer to provide establishment of a 3D model, the biomacromolecule material is added in biological ink, the solidifiable polymer can be assisted to further improve the ink viscosity, so that the mechanical strength of a final 3D model is better; and secondly, the biomacromolecule materialcan further provide substances required by part cells growing, and activity of the cells is guaranteed.

Described herein are novel rapid and reliable methods of detection of extracellular vesicles and quantifying extracellular vesicle concentrations and absolute number from various sources, including raw cell harvest. The methods described herein comprise detection of intrinsic fluorescence of extracellular vesicles in biological samples. Extracellular vesicles analyzed by the methods of this application have a stereotypical elution profile distinct from known contaminants. The methods described herein are a significant improvement over the state of the art and fulfills an unmet need in the field of extracellular vesicle manufacturing and quality control.

Methods for label-free characterization of untagged molecules within a biological sample in-situ. The untagged molecules may be constituent of extracellular vesicles, and are excited in the biological sample with at least one wavelength band of light derived from a single stream of optical pulses. Light emitted by the untagged molecules by SHG, THG, 2PAF and 3PAF processes is detected. Separate measures of the biological sample corresponding to light emitted by the untagged molecules in each of the SHG, THG, 2PAF and 3PAF processes are derived. On that basis, normal extracellular vesicles may be differentiated from extracellular vesicles associated with a tumor on the basis of a specified signature of characteristics of images of SHG, THG, 2PAF and 3PAF processes.